A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities

Sponsor
Eli Lilly and Company
Study ID
NCT06023095
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • LY3502970 — DRUG
    Administered orally.
  • Placebo — DRUG
    Administered orally.

Study Details

The main purpose of this study is to learn about the safety and tolerability of LY3502970 when given to Chinese participants with obesity or overweight with weight-related comorbidities. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive LY3502970, or placebo given orally. For each participant, the study will last about approximately 22- and 30-weeks for both cohort 1 and 2, respectively including screening period.

Key Dates

First listed
Sep 5, 2023
Start date
Sep 21, 2023
Status verified
Jun 2026
Primary completion
Jul 29, 2024
Completion
Jul 29, 2024

Study Design

Enrollment
24 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY3502970 (Cohort 1)
    Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 milligram (mg), 3 mg, 6 mg and then 12 mg LY3502970 administered orally once daily (QD) from Day 1 for 16 weeks.
  • Experimental: LY3502970 (Cohort 2)
    Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD from Day 1 for 24 weeks.
  • Placebo Comparator: Placebo
    Participants received placebo administered orally QD.

Primary Outcome Measure

Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline through Week 18 (Cohort 1) & Week 26 (Cohort 2) ]

Related coverage on Hipa.ai

Find similar trials

Nationwide
Obesity / overweight trialsEndocrinology trialsMetabolic health trialsWeight loss trials

Related Studies